Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.
Patients & Caregivers Healthcare Professionals Society & ESG Interim results from COMPACT, a multi-country, real-world study of Erelzi for approved rheumatic diseases presented at 2019 ACR/ARP Annual Meeting US analysis of long-term financial impact when switching to biosimilar etanercept
Ziextenzo(TM) is indicated to decrease the incidence of febrile neutropenia, one of the most serious side effects of chemotherapy - With approval of Ziextenzo(TM) , Sandoz is first and only company to offer US physicians longand short-acting filgrastim biosimilar treatment options - With four U
FDA placed a partial hold on AVXS-101 intrathecal clinical trials for SMA patients based on findings in a small pre-clinical animal study Adverse events that might be expected from the pre-clinical findings have not been seen in a thorough review of human safety data from all available sources to
Continuing operations 2 net sales up 13% (cc1, +10% USD) driven by: Cosentyx sales of USD 937 million (+27% cc), with strong demand across indications and regions Entresto USD 430 million (+61% cc), with increased demand in hospital and ambulatory settings Zolgensma sales of USD 160 million, strong
New two-year data compare the effects of Cosentyx (secukinumab) treatment in psoriatic arthritis patients with and without enthesitis, a manifestation described in 30-50% of patients - Results from a pooled analysis of two Phase 3 studies, show that patients treated with Cosentyx (n=477) had a
In two head-to-head clinical trials, patients on Beovu (brolucizumab) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of patients , - Beovu demonstrated greater reductions in central subfield thickness (CST, a key indicator o
Patients & Caregivers Healthcare Professionals Society & ESG - The FLIGHT- FXR phase IIb study showed tropifexor, a highly potent non-bile acid FXR agonist, produces robust and dose-dependent reductions in hepatic fat and alanine aminotransferase compared to placebo at 12 weeks - These da
Cosentyx narrowly missed statistical significance for superiority in ACR 20, the primary endpoint of the EXCEED trial, while showing numerically higher results versus Humira * - Statistically significant advantages of Cosentyx versus Humira * in psoriatic arthritis (PsA)-specific endpoints were
New Cosentyx (secukinumab) label to include 300 mg up-titration option is informed by results from the Phase III MEASURE 3 study - Approval provides clinicians with greater choice for their patients, based on clinical response to treatment - News follows recent announcement of submission to E
REACH2 trial results confirm Jakavi significantly improves overall response rate (ORR) at 28 days vs.
Data from five real-world evidence (RWE) and observational studies being conducted in North America, Latin America and Europe provide extensive cumulative insights for Cosentyx (secukinumab) clinical practice among more than 13,000 patients [1-6] - The studies report on the real-world sustained
Results from a Phase IIb dose-finding study show an average complete response rate of 42% for doses 240 mg and 72 mg ligelizumab at Week 12 compared with 26% for those taking 300 mg Xolair's dose (omalizumab) - Complete control of hives achieved by 51% and 42% of patients treated with ligelizum